DOP2010000112A - Productos quimioterapeuticos cristalinos - Google Patents

Productos quimioterapeuticos cristalinos

Info

Publication number
DOP2010000112A
DOP2010000112A DO2010000112A DO2010000112A DOP2010000112A DO P2010000112 A DOP2010000112 A DO P2010000112A DO 2010000112 A DO2010000112 A DO 2010000112A DO 2010000112 A DO2010000112 A DO 2010000112A DO P2010000112 A DOP2010000112 A DO P2010000112A
Authority
DO
Dominican Republic
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
indazol
Prior art date
Application number
DO2010000112A
Other languages
English (en)
Inventor
Michael J Rozema
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of DOP2010000112A publication Critical patent/DOP2010000112A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forma cristalina 1 de N-[4-(3-amino-1 H-indazol-4-il)fenil]-N'-(2-fluoro-5metilfenil)urea, maneras para elaborarla, formulaciones que comprenden a la misma y elaboradas con la misma y metodos de tratamiento de pacientes que padecen una enfermedad para usarla.
DO2010000112A 2007-10-19 2010-04-16 Productos quimioterapeuticos cristalinos DOP2010000112A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98125307P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
DOP2010000112A true DOP2010000112A (es) 2010-07-15

Family

ID=40174807

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000112A DOP2010000112A (es) 2007-10-19 2010-04-16 Productos quimioterapeuticos cristalinos

Country Status (18)

Country Link
US (1) US7960564B2 (es)
EP (1) EP2195301A1 (es)
JP (1) JP2011500707A (es)
KR (1) KR20100085987A (es)
CN (1) CN101827824B (es)
AU (1) AU2008312533A1 (es)
BR (1) BRPI0818334A2 (es)
CA (1) CA2699354A1 (es)
CO (1) CO6280484A2 (es)
CR (1) CR11443A (es)
DO (1) DOP2010000112A (es)
EC (1) ECSP10010176A (es)
GT (1) GT201000100A (es)
MX (1) MX2010004290A (es)
PA (1) PA8800601A1 (es)
RU (1) RU2010119919A (es)
UA (1) UA99489C2 (es)
WO (1) WO2009052230A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
BR112017002466A2 (pt) 2014-08-08 2017-12-05 Forsight Vision4 Inc formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2346538T3 (es) * 2003-05-22 2010-10-18 Abbott Laboratories Inhibidores de quinasa de tipo indazol, benzisoxazol y benzisotiazol.
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
DE102005033100B3 (de) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) * 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
WO2007050574A1 (en) 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
EP2195301A1 (en) 2010-06-16
JP2011500707A (ja) 2011-01-06
RU2010119919A (ru) 2011-11-27
CO6280484A2 (es) 2011-05-20
KR20100085987A (ko) 2010-07-29
CR11443A (es) 2010-09-27
MX2010004290A (es) 2010-04-30
CN101827824B (zh) 2012-10-03
PA8800601A1 (es) 2009-05-15
AU2008312533A1 (en) 2009-04-23
US20090124815A1 (en) 2009-05-14
GT201000100A (es) 2012-04-12
BRPI0818334A2 (pt) 2017-05-16
CN101827824A (zh) 2010-09-08
US7960564B2 (en) 2011-06-14
ECSP10010176A (es) 2010-06-29
CA2699354A1 (en) 2009-04-23
WO2009052230A1 (en) 2009-04-23
UA99489C2 (en) 2012-08-27

Similar Documents

Publication Publication Date Title
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
CY1115180T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
DOP2010000112A (es) Productos quimioterapeuticos cristalinos
DOP2010000111A (es) Productos quimioterapeuticos cristalinos
DOP2010000113A (es) Productos quimioterapeuticos cristalinos
DOP2010000116A (es) Productos quimioterapeuticos cristalinos
DOP2010000115A (es) Productos quimioterapeuticos cristalinos derivados de indazol
CR9074A (es) Agente para la profilaxis o tratamiento del sindrome metabolico
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
ITRM20030504A1 (it) Cura del calazio.